 Mind Medicine MindMed NASDAQ:MNMD, NEO:MMED Inc has earned a repeat Speculative Buy rating with a lowered price target of US18 from US22 per share from Canaccord Genuity TSX:CF, LSE:CF analysts following the release of its third-quarter results last week. The biotechnology companys shares are currently trading at about US2.60 per share. 